A pooled HR for progression-free survival in patients with high-expressing non-ovarian MAD2 tumours compared to those with low expressing MAD2 tumours was 1.29 (95% CI, 0.74–2.25; P = 0.38). This evidence concerns the gene MAD2L1 and neoplasm.